** Shares of drug developer Evoke Pharma more than double to $12.56 premarket
** Co says Gimoti, the nasal spray version of drug metoclopramide, when given to patients on GLP-1 weight loss treatments showed better reduction in symptoms compared to the oral version of metoclopramide
** EVOK says Gimoti can be used to treat patients on GLP-1 drugs with gastroparesis, a medical condition that prevents the stomach from emptying food and liquids properly
** Up to last close, stock down 58% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。